These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Prophylactic and therapeutic efficacy of a chimeric monoclonal antibody specific for H5 haemagglutinin against lethal H5N1 influenza. Prabhu N; Prabakaran M; Hongliang Q; He F; Ho HT; Qiang J; Goutama M; Lim AP; Hanson BJ; Kwang J Antivir Ther; 2009; 14(7):911-21. PubMed ID: 19918095 [TBL] [Abstract][Full Text] [Related]
30. [In vitro and in vivo effects of a long-acting anti-influenza agent CS-8958 (laninamivir octanoate, Inavir) against pandemic (H1N1) 2009 influenza viruses]. Kubo S; Kakuta M; Yamashita M Jpn J Antibiot; 2010 Oct; 63(5):337-46. PubMed ID: 21268406 [TBL] [Abstract][Full Text] [Related]
31. Generation and Characterization of Monoclonal Antibodies Specific to Avian Influenza H5N1 Hemagglutinin Protein. Malik A; Mallajosyula VV; Mishra NN; Varadarajan R; Gupta SK Monoclon Antib Immunodiagn Immunother; 2015 Dec; 34(6):436-41. PubMed ID: 26683184 [TBL] [Abstract][Full Text] [Related]
33. Exacerbation of influenza virus infections in mice by intranasal treatments and implications for evaluation of antiviral drugs. Smee DF; von Itzstein M; Bhatt B; Tarbet EB Antimicrob Agents Chemother; 2012 Dec; 56(12):6328-33. PubMed ID: 23027194 [TBL] [Abstract][Full Text] [Related]
36. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice. Lei H; Peng X; Jiao H; Zhao D; Ouyang J Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406 [TBL] [Abstract][Full Text] [Related]
37. Chimerization and characterization of a monoclonal antibody with potent neutralizing activity across multiple influenza A H5N1 clades. Mak TM; Hanson BJ; Tan YJ Antiviral Res; 2014 Jul; 107():76-83. PubMed ID: 24797696 [TBL] [Abstract][Full Text] [Related]
38. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Sidwell RW; Barnard DL; Day CW; Smee DF; Bailey KW; Wong MH; Morrey JD; Furuta Y Antimicrob Agents Chemother; 2007 Mar; 51(3):845-51. PubMed ID: 17194832 [TBL] [Abstract][Full Text] [Related]
39. Generation, characterization, and protective ability of mouse monoclonal antibodies against the HA of A (H1N1) influenza virus. Wang L; Yang F; Xiao Y; Chen B; Liu F; Cheng L; Yao H; Wu N; Wu H J Med Virol; 2022 Jun; 94(6):2558-2567. PubMed ID: 35005794 [TBL] [Abstract][Full Text] [Related]
40. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant. Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]